Nature Medicine, Published online: 13 January 2026; doi:10.1038/s41591-025-04164-x
MK-7762 is a new oxazolidinone antitubercular agent that is structurally similar to linezolid, and demonstrated in vivo efficacy, lesion penetration and limited toxicity compared to linezolid, indicating it could be used in broad tuberculosis regimens.
